Indeed, with the discovery of RSK-specific inhibitors further studies will need to be carried to verify the efficacy of RSK inhibitors as single agents or in combination with other anti-cancer agents in the lung cancer setting. This evidence concerns the gene RPS6KA1 and lung carcinoma.